Chen, Rui
Xie, Ruiling http://orcid.org/0000-0002-6086-8683
Meng, Zhipeng
Ma, Shenghong http://orcid.org/0000-0002-6335-7715
Guan, Kun-Liang http://orcid.org/0000-0003-1892-0174
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute (CA196878, CA196878, CA196878)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (CA196878)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (GM051586)
Article History
Received: 31 March 2019
Accepted: 25 October 2019
First Online: 2 December 2019
Change Date: 2 January 2020
Change Type: Correction
Change Details: An amendment to this paper has been published and can be accessed via a link at the top of the paper.
Competing interests
: K.-L.G. is a cofounder of and has an equity interest in Vivace Therapeutics, Inc. The terms of this arrangement have been reviewed and approved by the University of California San Diego in accordance with its conflict of interest policies.